View all the latest information in myeloproliferative neoplasms, arranged by therapeutic class and intervention. Listed below are recently updated therapeutic classes.
Predictive factors of mortality in patients with hematological malignancies diagnosed with COVID-19
During this COVID-19 pandemic, patients with hematological malignancies—who are immunocompromised...
COVID-19: Implications for patients with myeloproliferative neoplasms
Summary of two presentations at the Texas Virtual MPN Workshop (TMW) 2020: First Annual Workshop and Meeting. The first from MPN...
Polycythemia vera and essential thrombocythemia: 2021 updates
In a recent publication in the American Journal of Hematology, Tefferi and Barbui provided a review of the 2021 updates on the diagnosis,...
Educational theme: The role of interferon-alpha in the treatment of MPN
Interferons (IFN) are cytokines released by host cells to induce innate immune response against viral infections and are...
PTG-300 receives orphan drug designation from EMA for the treatment of PV
The European Medicines Agency (EMA) has granted orphan drug designation to PTG-300 for the treatment of polycythemia vera (PV).
U.S. FDA grants orphan drug designation for PTG-300 for the treatment of polycythemia vera
PTG-300, an injectable hepcidin mimetic peptide, has received orphan drug designation by the U.S. Food and...
Advances in allogeneic HSCT for patients with myelofibrosis
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only potentially curative treatment for patients with myelofibrosis...
The practical use of myelofibrosis genomics in a clinical setting
Myelofibrosis (MF), a subtype of the Philadelphia chromosome-negative myeloproliferative neoplasms (MPN), is characterized by Janus...
Non-steroidal anti-inflammatory drugs
PI3 kinase inhibitors